As we previously reported that serum HE4 is the optimal biomarker for blood-based prediction of surgical outcome (9), we can conclude from our present study that urinary HE4 is fully equivalent for this purpose, allowing urinary analysis to identify ovarian cancer patients, in whom a macroscopically complete resection will not be possible. The gene discussed is WFDC2; the disease is ovarian carcinoma.